These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 30704472)

  • 1. Comparison of different functional prediction scores using a gene-based permutation model for identifying cancer driver genes.
    Nono AD; Chen K; Liu X
    BMC Med Genomics; 2019 Jan; 12(Suppl 1):22. PubMed ID: 30704472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer driver gene discovery in transcriptional regulatory networks using influence maximization approach.
    Rahimi M; Teimourpour B; Marashi SA
    Comput Biol Med; 2019 Nov; 114():103362. PubMed ID: 31561101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pCADD: SNV prioritisation in Sus scrofa.
    Groß C; Derks M; Megens HJ; Bosse M; Groenen MAM; Reinders M; de Ridder D
    Genet Sel Evol; 2020 Feb; 52(1):4. PubMed ID: 32033531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. dbNSFP v3.0: A One-Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site SNVs.
    Liu X; Wu C; Li C; Boerwinkle E
    Hum Mutat; 2016 Mar; 37(3):235-41. PubMed ID: 26555599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A benchmark study of scoring methods for non-coding mutations.
    Drubay D; Gautheret D; Michiels S
    Bioinformatics; 2018 May; 34(10):1635-1641. PubMed ID: 29340599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies.
    Dong C; Wei P; Jian X; Gibbs R; Boerwinkle E; Wang K; Liu X
    Hum Mol Genet; 2015 Apr; 24(8):2125-37. PubMed ID: 25552646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of coding and non-coding mutational hotspots in cancer genomes.
    Piraino SW; Furney SJ
    BMC Genomics; 2017 Jan; 18(1):17. PubMed ID: 28056774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis Reveals the Functional Importance of Protein Lysine Modification in Cancer Development.
    Chen L; Miao Y; Liu M; Zeng Y; Gao Z; Peng D; Hu B; Li X; Zheng Y; Xue Y; Zuo Z; Xie Y; Ren J
    Front Genet; 2018; 9():254. PubMed ID: 30065750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
    Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
    Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence Neighborhoods Enable Reliable Prediction of Pathogenic Mutations in Cancer Genomes.
    Banerjee S; Raman K; Ravindran B
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34068918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CScape-somatic: distinguishing driver and passenger point mutations in the cancer genome.
    Rogers MF; Gaunt TR; Campbell C
    Bioinformatics; 2020 Jun; 36(12):3637-3644. PubMed ID: 32282885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ContrastRank: a new method for ranking putative cancer driver genes and classification of tumor samples.
    Tian R; Basu MK; Capriotti E
    Bioinformatics; 2014 Sep; 30(17):i572-8. PubMed ID: 25161249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating Non-Coding Annotations into Rare Variant Analysis.
    Richardson TG; Campbell C; Timpson NJ; Gaunt TR
    PLoS One; 2016; 11(4):e0154181. PubMed ID: 27128317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer driver gene discovery through an integrative genomics approach in a non-parametric Bayesian framework.
    Yang H; Wei Q; Zhong X; Yang H; Li B
    Bioinformatics; 2017 Feb; 33(4):483-490. PubMed ID: 27797769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PredictSNP2: A Unified Platform for Accurately Evaluating SNP Effects by Exploiting the Different Characteristics of Variants in Distinct Genomic Regions.
    Bendl J; Musil M; Štourač J; Zendulka J; Damborský J; Brezovský J
    PLoS Comput Biol; 2016 May; 12(5):e1004962. PubMed ID: 27224906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revealing selection in cancer using the predicted functional impact of cancer mutations. Application to nomination of cancer drivers.
    Reva B
    BMC Genomics; 2013; 14 Suppl 3(Suppl 3):S8. PubMed ID: 23819556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing for association with rare variants in the coding and non-coding genome: RAVA-FIRST, a new approach based on CADD deleteriousness score.
    Bocher O; Ludwig TE; Oglobinsky MS; Marenne G; Deleuze JF; Suryakant S; Odeberg J; Morange PE; Trégouët DA; Perdry H; Génin E
    PLoS Genet; 2022 Sep; 18(9):e1009923. PubMed ID: 36112662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinguishing between driver and passenger mutations in individual cancer genomes by network enrichment analysis.
    Merid SK; Goranskaya D; Alexeyenko A
    BMC Bioinformatics; 2014 Sep; 15(1):308. PubMed ID: 25236784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying cancer driver genes in tumor genome sequencing studies.
    Youn A; Simon R
    Bioinformatics; 2011 Jan; 27(2):175-81. PubMed ID: 21169372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined burden and functional impact tests for cancer driver discovery using DriverPower.
    Shuai S; ; Gallinger S; Stein LD;
    Nat Commun; 2020 Feb; 11(1):734. PubMed ID: 32024818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.